Kelowna, British Columbia – October 16, 2025 – TheNewswire - Rize Oncology Inc. (the “ Company ”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced the resignation of Daren Graham as Executive Chairman and interim Chief Executive Officer of the Company. P. Gage Jull, a current Director of the Company, has been appointed the Company’s interim Chief Executive... Read More

Kelowna, British Columbia – July 10, 2025 – TheNewswire - Rize Oncology Inc. (the “ Company ”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced that it has appointed Executive Chairperson Daren Graham as the Company’s interim Chief Executive Officer. Mr. Graham’s appointment will be effective July 10, 2025 and coincides with the resignation of Roland Boivin as... Read More

Kelowna, British Columbia – May 16, 2025 – TheNewswire – Rize Oncology Inc. (CSE: RIZE) (“Rize Oncology” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced several strategic developments to support the ongoing advancement of its drug candidate, STS-201. The Company has received the approval of a simple majority of its disinterested shareholders,... Read More

Kelowna, British Columbia – April 22, 2025 – TheNewswire - Rize Oncology Inc. (CSE: RIZE) (“Rize” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced that its Board of Directors has authorized the Company to seek shareholder approval for the voluntary delisting of its common shares from the Canadian Securities Exchange (“CSE”).​ The proposed... Read More

Kelowna, British Columbia – January 9, 2025 – TheNewswire – GeneTether Therapeutics Inc. (CSE: GTTX) today announced that it has changed its name to Rize Oncology Inc. (“Rize” or the “Company”). This rebranding reflects the Company's strategic shift towards oncology, particularly soft tissue sarcoma, highlighted by the recent exclusive licensing of STS-201, a promising small molecule targeting soft tissue sarcoma and other... Read More

Kelowna, British Columbia – January 6, 2025 – TheNewswire - GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneT ether, Inc., “GeneTether” or the “Company”) (CSE: GTTX) is pleased to announce the successful closing of its two previously announced transactions: Licensing Agreement for STS-201 The Company has successfully closed the previously announced licensing agreement for STS-201 (the “ License... Read More

Kelowna, British Columbia – TheNewswire - December 12, 2024 – GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE: GTTX) is pleased to announce that all resolutions presented to shareholders at the Company’s Annual General and Special Meeting of Shareholders (the " AGM ") held earlier today were approved by the requisite majority of shareholders.... Read More

December 6, 2024 – TheNewswire – Kelowna, BC – GeneTether Therapeutics Inc. (CSE: GTTX) (“ GeneTether ” or the “ Company ”) is pleased to provide additional information concerning its previously announced transaction pursuant to which EGB Ventures (through its operating entity) (“ EGB ”) would grant the Company an exclusive license of EGB’s STS-201, a small molecule that has exhibited significant utility in soft tissue... Read More

Vancouver, British Columbia – December 2, 2024 – TheNewswire – GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE: GTTX) is providing an update to its shareholders regarding the potential impact of the strike by the Canadian Union of Postal Workers on the Company's ability to comply with its obligations to deliver its meeting materials to... Read More

Vancouver, British Columbia – November 22, 2024 – TheNewswire - GeneTether Therapeutics Inc. ( together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE: GTTX) announced today the filing of its interim condensed consolidated financial statements for the third quarter of 2024. All dollar amounts are presented in the United States dollar, unless otherwise noted. Complete financial... Read More

KELOWNA, BC & SAN JUAN, PR – October 11, 2024 – TheNewswire – GeneTether Therapeutics Inc. (CSE: GTTX) (“ GeneTether ” or the “ Company ”) today announced entry into a binding term sheet (the “ Term Sheet ”) with EGB Ventures (through its operating entity) (“ EGB ”) pursuant to which EBG would grant the Company an exclusive license of EGB’s STS-201, a small molecule that has exhibited significant utility in soft tissue... Read More

Vancouver, British Columbia – TheNewswire - August 23, 2024 – GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE: GTTX) announced today the filing of its interim condensed consolidated financial statements for the second quarter of 2024. All dollar amounts are presented in the United States dollar, unless otherwise noted. Complete financial... Read More

Vancouver, British Columbia – May 29, 2024 – TheNewswire – GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE: GTTX) announced today the filing of its interim condensed consolidated financial statements for the first quarter of 2024. All dollar amounts are presented in the United States dollar, unless otherwise noted. Complete financial statements... Read More

Vancouver, British Columbia (TheNewswire) – March 28, 2024 – GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE: GTTX) announced today the filing of its audited financial statements for the fiscal year ending December 31, 2023, and reported on corporate highlights from 2023. All dollar amounts are presented in the United States dollar, unless... Read More

Vancouver, British Columbia - TheNewswire - November 28, 2023 - GeneTether Therapeutics Inc. (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE:GTTX) announced today the filing of its interim condensed consolidated financial statements for the period ending September 30, 2023. All dollar amounts are presented in the United States dollar, unless otherwise noted. Complete... Read More

Vancouver, British Columbia – TheNewswire - October 20, 2023 – GeneTether Therapeutics Inc. , (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE:GTTX), today provided the following update to shareholders from the Company’s Board of Directors: Dear GeneTether Shareholders, We hope this message finds you in good health and optimistic about the future of the economy. On behalf... Read More

Vancouver, British Columbia - TheNewswire - August 25, 2023 - GeneTether Therapeutics Inc. , (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE:GTTX) , an early-stage genetic medicine company focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome, announced today the filing of its interim... Read More

Vancouver, B C - TheNewswire - May 25, 2023 - GeneTether Therapeutics Inc. , (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE:GTTX) , an early-stage genetic medicine company focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome, announced today the filing of its interim condensed... Read More

Vancouver, British Columbia – TheNewswire - May 1 st , 2023 - GeneTether Therapeutics Inc. (“ GeneTether ” or the “ Company ”) (CSE:GTTX), is pleased to announce the engagement of Mr. Gad Berdugo, Managing Partner of Explorium Capital LLC, as an advisor to explore strategic alternatives for its GeneTether™ platform technology. Mr. Berdugo, who served as the former Chief Business Officer of gene editing pioneer, Editas,... Read More

Vancouver, BC - TheNewswire - April 27, 2023 - GeneTether Therapeutics Inc. , (together with its wholly-owned subsidiary GeneTether, Inc., “ GeneTether ” or the “ Company ”) (CSE:GTTX) , an early-stage genetic medicine company focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome, announced today the filing of its audited financial... Read More

Vancouver, BC - TheNewswire - March 30, 2022 - GeneTether Therapeutics Inc. (“ GeneTether ” or the “ Company ”) (CSE:GTTX) is pleased to provide an update from the CEO. Dear Shareholders, I hope this update finds you well. As I’ve recently mentioned, we have made the decision to scale back development of our patented GeneTether™ platform technology and explore strategic alternatives that will optimize shareholder value. This... Read More

Vancouver, BC - TheNewswire - February 8, 2023 - GeneTether Therapeutics Inc. (“ GeneTether ” or the “ Company ”) (CSE:GTTX) , a preclinical-stage biotechnology company focused on developing its proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies, today provides the following update on its development pipeline and... Read More

Vancouver, British Columbia – TheNewswire - November 25, 2022 – GeneTether Therapeutics Inc. (“ GeneTether ” or the “ Company ”) (CSE:GTTX), announced today the filing of its interim condensed consolidated financial statements for the period ending September 30, 2022 and reported on corporate highlights for the third quarter of fiscal 2022. GeneTether is an early-stage genetic medicine company focused on developing its... Read More